Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Groen, H. J. M.
Right arrow Articles by Mulder, N. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Groen, H. J. M.
Right arrow Articles by Mulder, N. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:427-432, 2004
© 2004 European Society for Medical Oncology

Original Paper

Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study

Received 20 May 2003; revised 4 November 2003; accepted 17 December 2003

Purpose:

To determine the radiosensitizing effect of prolonged exposure of carboplatin in patients with locally unresectable non-small-cell lung cancer (NSCLC).

Patients and methods:

Patients with histologically proven NSCLC, performance score <2, weight loss <10%, and normal organ functions were randomized between carboplatin 840 mg/m2 administered continuously during 6 weeks of radiotherapy or thoracic radiotherapy alone (both 60 Gy). Toxicity was evaluated with National Cancer Institute Common Toxicity Criteria (NCI CTC) and the Radiation Therapy Oncology Group (RTOG) criteria. Quality of life was measured with European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30/LC13 questionnaires.

Results:

One-hundred and sixty patients were included. Pathologically confirmed persistent tumor was present in 53% of patients in the combination arm versus 58% in the radiotherapy alone arm (P = 0.5). Median survival in the combination arm was 11.8 [95% confidence interval (CI) 9.3–14.2] months and in the radiotherapy alone arm 11.7 (95% CI 8.1–15.5) months; progression-free survival was not different between arms [6.8 and 7.5 months, respectively (P = 0.28)]. Acute toxicity was mild, late toxicity was radiation-induced cardiomyopathy (three patients) and pulmonary fibrosis (five patients). Quality of life was not different between arms, but in all measured patients cough and dyspnea improved, pain became less, and slight paresthesia developed 3 months after treatment.

Conclusion:

Addition of continuously administered carboplatin as radiosensitizer for locally unresectable NSCLC does not improve local tumor control or overall survival.

H. J. M. Groen1,*, A. H. W. van der Leest1, E. Fokkema1, P. R. Timmer2, G. D. Nossent3, W. J. G. M. Smit4, J. Nabers4, H. J. Hoekstra1, J. Hermans5, R. Otter6, J. W. G. van Putten1, E. G. E. de Vries1 and N. H. Mulder1

1 University Hospital Groningen, 2 Radiotherapeutic Institute Zwolle, 3 Martini Hospital Groningen, 4 Radiotherapeutic Institute and Medical Center Leeuwarden, 5 Department of Statistics, Leiden, and 6 Comprehensive Cancer Center North-Netherlands, The Netherlands

Key words: carboplatin, NSCLC, radiosensitization, radiotherapy, stage III


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
B. Jeremic
Reply to the article "Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study", by Groen et al. (Ann Oncol 2004; 15: 427-432)
Ann. Onc., August 1, 2004; 15(8): 1298 - 1299.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.